Related Experiment Video
Updated: Jun 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
[Research progress on gene mutation of jak2]
1Cancer Center, The First Hospital, Jilin University, Changchun 130021, Jilin Province, China.
Insights
Chronic myeloproliferative diseases (CMPD) involve abnormal blood cell growth. Recent research highlights the JAK2 gene mutation
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Context:
- Chronic myeloproliferative diseases (CMPD) are a group of clonal hematopoietic stem cell disorders.
- CMPD encompasses conditions like polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
- The exact pathogenesis of most CMPDs remains elusive, except for chronic myeloid leukemia (CML) linked to the BCR-ABL fusion gene.
Purpose:
- To review the association of the JAK2 gene mutation with CMPD.
- To explore the role of JAK2 mutations in the clinical diagnosis and features of CMPD.
- To summarize the implications of JAK2 mutations for molecular targeted therapy in CMPD and related hematological disorders.
Summary:
- The JAK2 gene mutation is frequently observed in patients with chronic myeloproliferative diseases (CMPD).
- This review consolidates current understanding of JAK2 mutations in relation to CMPD diagnosis, clinical presentation, and therapeutic strategies.
- JAK2 mutations are a significant factor in understanding the molecular basis and treatment of CMPD.
Impact:
- Highlights the importance of JAK2 mutation analysis for accurate CMPD diagnosis.
- Provides insights into the molecular mechanisms driving CMPD pathogenesis.
- Informs the development and application of targeted therapies for CMPD patients.
Abstract:
Chronic myeloproliferative disease (CMPD) is a group of malignant blood disorders including polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloid leukemia, and so on. CMPD is characterized by proliferation of one or several lineages in hematopoietic system. The pathogenesis of CMPD is not clear except chronic myeloid leukemia associated with the bcr/abl fusion gene. In recent years, more studies demonstrated that CMPD have a higher mutation rate of gene jak2. In this review, the association of jak2 gene mutation with clinical diagnosis, clinical feature and molecular target therapy in CMPD and other hematological disease were summarized.
Related Concept Videos
The JAK-STAT Signaling Pathway
Spontaneous and Induced Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Mutations
Mutations
In vitro Mutagenesis

